Education
About Us
Working with TipRanks
Follow Us
Aptevo Therapeutics Inc (APVO)
NASDAQ:APVO
APVO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.32 - $381.75
Previous CloseN/A
Volume25.11K
Average Volume (3M)8.87M
Market Cap
$4.73M
Enterprise Value-$2.95M
Total Cash (Recent Filing)$9.41M
Total Debt (Recent Filing)$4.21M
Price to Earnings (P/E)―
Beta-0.36
Next Earnings
Nov 06, 2025EPS Estimate
-2.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.40
Shares Outstanding3,287,918
10 Day Avg. Volume26,245,572
30 Day Avg. Volume8,868,414
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.25
Price to Sales (P/S)0.00
P/FCF Ratio-0.05
Enterprise Value/Market Cap-0.62
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit12.55
Enterprise Value/Ebitda0.12
Forecast
1Y Price Target
$21.00Price Target Upside1410.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Aptevo Therapeutics News
APVO FAQ
What was Aptevo Therapeutics Inc’s price range in the past 12 months?
Aptevo Therapeutics Inc lowest stock price was $1.32 and its highest was $381.75 in the past 12 months.
What is Aptevo Therapeutics Inc’s market cap?
Aptevo Therapeutics Inc’s market cap is $4.73M.
When is Aptevo Therapeutics Inc’s upcoming earnings report date?
Aptevo Therapeutics Inc’s upcoming earnings report date is Nov 06, 2025 which is in 35 days.
How were Aptevo Therapeutics Inc’s earnings last quarter?
Aptevo Therapeutics Inc released its earnings results on Aug 11, 2025. The company reported -$8.4 earnings per share for the quarter, beating the consensus estimate of -$83.2 by $74.8.
Is Aptevo Therapeutics Inc overvalued?
According to Wall Street analysts Aptevo Therapeutics Inc’s price is currently Undervalued.
Does Aptevo Therapeutics Inc pay dividends?
Aptevo Therapeutics Inc does not currently pay dividends.
What is Aptevo Therapeutics Inc’s EPS estimate?
Aptevo Therapeutics Inc’s EPS estimate is -2.09.
How many shares outstanding does Aptevo Therapeutics Inc have?
Aptevo Therapeutics Inc has 3,287,918 shares outstanding.
What happened to Aptevo Therapeutics Inc’s price movement after its last earnings report?
Aptevo Therapeutics Inc reported an EPS of -$8.4 in its last earnings report, beating expectations of -$83.2. Following the earnings report the stock price went down -4.867%.
Which hedge fund is a major shareholder of Aptevo Therapeutics Inc?
Currently, no hedge funds are holding shares in APVO
Company Description
Aptevo Therapeutics Inc
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Technical Analysis
VivoSim Labs
―
Enveric Biosciences
―
Ensysce Biosciences
―
Revelation Biosciences
―
Tao Synergies
―
Ownership Overview
<0.01% Insiders
0.02% Mutual Funds
0.03% Other Institutional Investors
99.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---